文献速递肝病胃肠动力与功能性疾病

Saroglitazar改善PCOS合并MASLD女性肝脂肪变及肝酶:多中心双盲安慰剂对照研究

Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study.
PubMed 文献 · Hepatology · 2026-10-15

这项多中心随机双盲安慰剂对照2A期试验纳入60例18-45岁PCOS合并MASLD女性,按1:1随机接受saroglitazar 4 mg或安慰剂治疗24周。主要终点为MRI质子密度脂肪分数所测肝脂肪含量的相对变化,符合方案集分析显示saroglitazar组肝脂肪含量较基线显著下降,且≥30%降幅比例更高,肝酶、血脂及FibroScan AST评分亦改善,不良事件与安慰剂相当。

要点

  • Saroglitazar 4 mg治疗24周可显著降低PCOS合并MASLD女性肝脂肪含量。
  • Saroglitazar组达MRI-PDFF降幅≥30%者比例显著高于安慰剂组。
  • Saroglitazar还改善转氨酶、血脂参数及FibroScan AST评分,安全性可接受。

核心结论

  • 在PCOS合并MASLD女性中,saroglitazar显著改善肝脂肪变、肝酶、血脂谱及FibroScan AST评分,支持在更大规模研究中进一步评估。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2A期试验,60例18-45岁PCOS合并MASLD女性按1:1随机接受saroglitazar 4 mg或安慰剂治疗24周。
  • 主要终点为MRI质子密度脂肪分数所测肝脂肪含量的相对(百分比)变化,主要分析在符合方案集(saroglitazar组25例、安慰剂组23例)中进行。

主要发现

  • 24周时saroglitazar组肝脂肪含量百分比较基线显著下降,安慰剂组为上升(最小二乘均值±SE:-14.81±5.52 vs. 1.96±5.75,p=0.041)。
  • 控制基线HbA1c不平衡后,saroglitazar的获益更明显(最小二乘均值±SE:-18.93±4.83 vs. 6.43±5.04,p<0.009)。
  • saroglitazar组达到MRI-PDFF降幅≥30%的比例显著高于安慰剂组(36.0% vs. 8.7%;p=0.025)。
  • saroglitazar还显著降低转氨酶水平、血脂参数及FibroScan AST评分。
  • 两组不良事件相当,均无严重不良事件;saroglitazar组1例妊娠母婴结局平稳。

关键数值与推荐

  • 主要终点为24周MRI质子密度脂肪分数所测肝脂肪含量相对(百分比)变化(p=0.041)。
  • MRI-PDFF降幅≥30%的比例:saroglitazar组36.0% vs. 安慰剂组8.7%(p=0.025)。

临床怎么用

  • 对于PCOS合并MASLD的女性,saroglitazar 4 mg每日治疗24周可考虑用于改善肝脂肪变及肝酶,但需在更大规模研究中进一步验证。

局限性

  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Polycystic ovary syndrome (PCOS) is the leading endocrine disorder in reproductive-age women. Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in women with PCOS, but they are underrepresented in MASLD therapeutic trials. We evaluated the safety and efficacy of saroglitazar, a novel peroxisome proliferator-activated receptors α/γ agonist, for the treatment of hepatic steatosis in women with PCOS and MASLD. METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase 2A trial, 60 women (18-45 y) with PCOS and MASLD were randomized 1:1 to either saroglitazar 4 mg or placebo for 24 weeks. The primary endpoint was relative (percent) change in hepatic fat content, measured by MRI proton density fat fraction. Primary analysis was performed in the per-protocol population (saroglitazar: 25; placebo: 23). RESULTS: Participants in the saroglitazar group showed a significant reduction in percent hepatic fat content at 24 weeks from baseline compared to placebo ([least squares mean±SE]: -14.81±5.52 vs. 1.96±5.75, p =0.041). When controlled for baseline HbA1c imbalance, the beneficial effect of saroglitazar was more pronounced ([least squares mean±SE]: -18.93±4.83 vs. 6.43±5.04, p <0.009). A higher proportion in the saroglitazar group achieved ≥30% reduction in magnetic resonance imaging-proton density fat fraction (36.0% vs. 8.7%; p =0.025). Saroglitazar also significantly reduced aminotransferase levels, lipid parameters, and the FibroScan AST score. Adverse events were comparable between the groups, and none were serious. One pregnancy in the saroglitazar arm resulted in uneventful maternal and neonatal outcomes. CONCLUSIONS: In women with PCOS and MASLD, saroglitazar significantly improved hepatic steatosis, liver enzymes, lipid profile, and FibroScan AST score. These findings support further evaluation of saroglitazar in larger studies in women with PCOS.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Samala N, González-González J, Jenders RA, et al. Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study. Hepatology. 2026. PMID: 42879243. doi:10.1097/HEP.0000000000001862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。